Ormeval provides decision-support intelligence derived from public sources. It is not investment, medical, legal or regulatory advice, and states nothing about the value of any security. Forward figures are deterministic model estimates, not guidance.
No material change since 1 Jul 2026
Latest quarter · Q2 2026
$1,695M▲44% YoY
Reported · year-on-year
next: Q3 2026 · results date not yet announced
Year to date
fiscal year start not on record
Full year · FY2025
$4.78B▲58% YoY
Reported · Novartis FY2025 results
Modelled peak
$9.73B2030
Model estimate · not risk-adjusted
US LOE
Nov 2031
US exclusivity window · Novartis FY2025 20-F
Reported, public fact, citedModel, Ormeval estimateHover any figure for its source.Tap any figure for its source.
Refresh cadenceFinancials · FY2025 reportedMarket & label · Q2 2026Catalysts · refreshed daily
The CDK4/6 inhibitor with the class's strongest metastatic overall-survival record, now Novartis's fastest-growing asset on the broadest adjuvant label in the class - and the only one of the three still growing.
The 15-second verdict
The CDK4/6 inhibitor with the class's strongest metastatic overall-survival record, now Novartis's fastest-growing asset on the broadest adjuvant label in the class - and the only one of the three still growing.
Can NATALEE's breadth - Stage II–III high-risk disease including node-negative patients - beat monarchE's depth, a seven-year adjuvant overall-survival result Kisqali has not yet produced?
Bottom line
Breadth is winning commercially, but the evidence gap is real and does not close until 2030. Kisqali's adjuvant indication covers a materially larger population than Verzenio's node-positive-only label, and revenue reflects it at ▲58% in FY2025. But Lilly reported monarchE seven-year adjuvant overall survival at ESMO 2025 (HR 0.842, p=0.027) while Novartis stated at the same congress that NATALEE overall survival remains immature, and NATALEE's own primary completion is 29 May 2030. The model still climbs to a $9.73B CONCLUDED peak (2030) behind Orange Book patents running to Nov 2031 - carried by population size and the MONALEESA survival record, not yet by an adjuvant survival result.
◆ Ormeval scoping estimateThe $9.73B peak above is computed by the model, not company guidance.
The full bull / base / bear framing sits in the launch wave vs. threat bridge →
Kisqali is Novartis's fastest-growing major oncology asset (~$4.8B FY2025, +58% YoY), and the surge is being driven almost entirely by the NATALEE expansion into high-risk Stage II–III HR+/HER2- early breast cancer, which dramatically widens the eligible population beyond the metastatic setting. Among the three marketed CDK4/6 inhibitors, ribociclib is differentiated by consistent overall-survival benefit across the MONALEESA program, the strongest OS dataset in the class, which underpins its competitive case against Lilly's Verzenio and Pfizer's Ibrance.
With latest Orange Book patents running to Nov 2031 and no generic approved, the franchise has a long runway; the defining question is how deeply it can penetrate the adjuvant early-BC market against Verzenio's first-mover position there. This is the clearest growth engine in Novartis's portfolio.
Molecule
ClassCDK4/6 inhibitor
TargetCyclin-dependent kinases 4 and 6
ModalityOral small molecule
Dosing600 mg PO once daily, 3 wks on / 1 wk off
Safety & tolerability at a glanceFull profile →
Reported, FDA labelClass estimate1Reported rows are transcribed from the US prescribing information; dashed rows are class-level estimates. Open a row for the curated sentence behind it.
Development to approval
Development to approval
First-in-human NCT01237236 (LEE011 in advanced solid tumours or lymphoma) opened 21 Dec 2010. There was no separate registrational Phase 2 in advanced breast cancer - the endocrine-combination dose and 3-weeks-on/1-week-off schedule came out of Phase 1b expansion cohorts and the programme went straight into Phase 3. MONALEESA-2 (NCT01958021, ribociclib plus letrozole) opened 17 Dec 2013 with primary completion 29 Jan 2016, and FDA approved Kisqali in Mar 2017: just over six years from first dose. The adjuvant expansion that now drives the franchise is a far longer bet - NATALEE (NCT03701334) opened 7 Dec 2018 and does not reach its listed primary completion until 29 May 2030, which is when a mature overall-survival analysis becomes available.
9 sections · 8 curated · 1 engine-derived by design (8 of 8 curatable)
All 2 indication rows were checked against a named source, 16 Aug 2026.
A dash means that section is not yet curated for this asset and falls back to a derived estimate or an illustrative default, it is never presented as a sourced figure. ≈ marks a section the engine derived from the indication models rather than one curated for this asset; it is real output, but it is not counted as curated. A few sections carry the same ≈ permanently: the revenue mix is computed from the indication models and has no curated form to replace it, so it is shown but left out of the count rather than standing as a gap that never closes.
What it shows. The asset's revenue trajectory: reported actuals where available, then the modelled outlook, summed across all of its indications.
What to look for. The growth slope into peak and the drop after loss of exclusivity, that cliff is the defining risk for a marketed asset.
Common misread. The forward portion is a modelled scenario, not company guidance; and it is the asset total, the per-indication pages show what each one contributes.
Since 2026-09-29: peak $9.73B (2030) vs $9.73B (2030), unchanged; 2031 $9.73B vs $9.73B, unchanged
Solid line = reported revenue; dashed line and band = Ormeval's modelled outlook from the current year.
2 of the 4 headline figures are cited to a document; the other 2 are flagged model estimates.
How the $9.73B · 2030 peak is derivedCONCLUDED · model estimate
Model-derived, not company guidance: the $9.73B 2030 peak extends the reported trajectory (FY2025 $4.78B, +58% YoY) forward, held inside exclusivity to ~2031, after which a ~20%/yr erosion applies. An Ormeval model output, not company guidance or analyst consensus.
How accurate have our forecasts been? See the track record →
LOE Horizon: Latest Orange Book patents (US 9,193,732 / 9,868,739) expire Nov 2031; composition patent to Jun 2028. No generic approved.
Key threat, monarchE's seven-year adjuvant overall survival - an argument NATALEE cannot answer until 2030
resolves not before 29 May 2030 (NATALEE primary completion)Kisqali's commercial case is overall survival: it is the CDK4/6 inhibitor with consistent OS benefit across MONALEESA-2, -3 and -7, and that is the argument that moved prescribers off Ibrance. In the adjuvant setting, where the growth now is, that argument currently runs the other way. At ESMO 2025 Lilly reported monarchE seven-year adjuvant overall survival with a hazard ratio of 0.842 (p=0.027).
At the same congress Novartis presented the five-year NATALEE analysis - a 28.4% reduction in risk of recurrence, five-year iDFS 85.5% versus 81.0%, sustained two years past the end of the three-year treatment period - and stated explicitly that overall survival remains immature. NATALEE's listed primary completion is 29 May 2030, so the gap stays open for four more years while adjuvant guideline and formulary positions are being set. Kisqali's counter is population: its label covers Stage II–III high-risk disease including node-negative patients, which Verzenio's node-positive-only adjuvant indication does not reach. The second constraint sits inside NATALEE itself - 20% of adjuvant patients permanently discontinued for an adverse reaction and 73% needed a dose interruption, which bounds how much of that broader eligible population converts into treated years.
◆ Ormeval scoping estimateEvery figure below is computed by the model from public sources. None is company guidance.
What's at risk
The adjuvant growth engine
the NATALEE expansion is what produced ▲58% in FY2025; Novartis publishes no adjuvant-versus-metastatic revenue split
Timing
Now through 2030
guideline and formulary choices are being made against monarchE's OS today, not at NATALEE's readout
Resolving readout
NATALEE mature OS
NCT03701334, listed primary completion 29 May 2030
Model impact
Caps adjuvant share, does not remove it
the record applies no erosion before 2031; Orange Book patents run to Nov 2031
Want to edit assumptions and model scenarios? Set up your cockpit →
Every material move on this page, newest first, the public fact, and what our model made of it.
Share of modelled indication revenue · 2026 · 2 of 4 approved indications modelled · not the reported total (why)
The single biggest earner is HR+/HER2- EARLY BC, adjuvant, Stage II–III high-risk (+ AI) at 52%, followed by the next 1.
Shares are of modelled net revenue in 2026 across the indications that carry a model; they are not shares of the reported FY figure, and the modelled values are not summed into a total here. Pre-revenue rows show the modelled peak. Every figure is an Ormeval model projection, not company guidance.
Regional revenue split
Disclosed shares · derived figures
Reference: Q2 2026 reported revenue of $1.70B, the latest reported earnings.
US
62.2%$1.06B
RoW
37.8%$640M
Percentages are Ormeval's regrouping (FY2025) of the regions the company itself reports: US / Rest of world / Total; net sales to third parties by location of customer; applying them to the Q2 2026 total is ours. Regions the company does not break out separately are not listed here, an absent region means “not separately disclosed”, never zero sales. Follow this asset to model your own.
Follow to edit →Loss of exclusivity is the forecast's biggest assumption. When it falls in each market, what gates it, who is coming, and what the forecast assumes.
1 · When, by market
today (2026) to the gating expiry
3 · Who is coming
No biosimilar or generic programme on record: no ClinicalTrials.gov census has been taken for this asset as of Q2 2026, so this is an unverified absence, not a finding that none exists.
Four ANDAs with Paragraph IV certifications were submitted to FDA on 15 March 2021 against NDA 209092 (and four against the 209935 co-pack) - the earliest permissible NCE-1 date. Litigants of record in D. Del. are MSN Pharmaceuticals / Novadoz Pharmaceuticals and Natco Pharma Limited; dockets 1:21-cv-00981, 1:21-cv-01102, 1:23-cv-00550, 1:24-cv-01193 (MSN) and 1:24-cv-01033 (Natco), plus appeal 25-1550. Secondary reporting indicates the MSN dispute ended in a confidential Settlement and License Agreement and the Natco case was dismissed with prejudice on 1 May 2025; the licensed entry dates are not public. The identity of the other two first filers is not disclosed in FDA's list. A tentatively approved ribociclib tablets application (215976) exists, consistent with a generic cleared on the merits but blocked by patents and exclusivity. No generic ribociclib is on the US market as of 3 August 2026.
4 · What the forecast assumesModel
The erosion assumption is drawn on the revenue outlook.
2 · What gates it
statuses as of Oct 15, 2026
Modality Small molecule (NCE) - CDK4/6 inhibitor, marketed as ribociclib succinate tablets. Governed by the Hatch-Waxman regime: listed in the FDA Orange Book with patents and exclusivity codes, subject to ANDA submission with Paragraph IV certification, 30-month stays and 180-day first-filer exclusivity. Not a biologic and not subject to the BPCIA. · First licensure 13 March 2017, United States, NDA 209092 (KISQALI, ribociclib succinate tablets, Novartis Pharmaceuticals Corp.), approved as a new chemical entity. A companion co-packaged product, KISQALI FEMARA CO-PACK, was approved 4 May 2017 under NDA 209935. IND for LEE011 effective 26 August 2010; NDA initially submitted 29 August 2016.
| Layer | Date | Status | Source |
|---|---|---|---|
5-year NCE exclusivity - EXPIREDFive years from the 13 March 2017 NCE approval of NDA 209092. The NCE-1 carve-out allowed Paragraph IV ANDAs to be submitted from 13 March 2021; FDA's Paragraph IV Certifications list records the first substantially complete submission on 15 March 2021 (13 March 2021 fell on a Saturday). This layer is long gone and is listed only so the timeline is re-derivable. | 20222022-03-13 | lapsed | FDA Paragraph IV Patent Certifications list - Ribociclib Succinate Tablets, NDA 209092, date of submission 15 Mar 2021, 4 ANDAs submitted |
Composition-of-matter patent US 8,415,355, extended under 35 U.S.C. 156, plus 6-month paediatric exclusivityThe Orange Book patent file lists US 8,415,355 against NDA 209092 and NDA 209935 with drug-substance AND drug-product flags and an expiry of 13 March 2031, and separately lists 8415355*PED at 13 September 2031. The 13 Mar 2031 date is re-derivable: Novartis's PTE application recorded the unextended term as 19 February 2031, and 35 U.S.C. 156(c)(3) caps total term at 14 years from approval, i.e. 13 Mar 2017 plus 14 years = 13 Mar 2031, so only 22 days of the requested restoration could be granted. Paediatric exclusivity then adds six months, giving 13 Sep 2031. Novartis's own FY2025 Form 20-F patent table independently states Kisqali US expiry 2031 (EU 2032). | 20312031-09-13 | confirmed | FDA Orange Book data files (patent.txt / exclusivity.txt, July 2026 edition) |
Second drug-substance patent US 9,193,732 plus paediatric exclusivityOrange Book lists US 9,193,732 against NDA 209092 and 209935 with both drug-substance and drug-product flags, expiring 9 November 2031, and 9193732*PED at 9 May 2032. Because it carries a drug-substance flag it is harder for a generic to design around than a pure formulation patent, so it is a credible secondary gate roughly eight months beyond the extended compound patent. Also listed: US 8,324,225 (17 Jun 2028, PED 17 Dec 2028) and US 8,685,980 (25 May 2030, PED 25 Nov 2030), both drug-substance flagged. | 20322032-05-09 | confirmed | FDA Orange Book data files (patent.txt, July 2026 edition) |
Formulation / drug-product patent stack US 10,799,506, US 12,064,434, US 12,419,894 plus paediatric exclusivityThree Orange Book patents carry only the drug-product flag and all expire 14 April 2036, with paediatric expiry 14 October 2036. FDA's own Paragraph IV list gives 14 Apr 2036 as the expiration date of last qualifying patent for Kisqali. These are formulation patents, not compound patents: a generic can and routinely does certify around or design around them, so this stack should be treated as the optimistic upper bound for Novartis rather than the planning case. Also listed are US 9,416,136 (20 Aug 2029, PED 20 Feb 2030), US 8,962,630 (9 Dec 2029, PED 9 Jun 2030), US 9,868,739 (9 Nov 2031, PED 9 May 2032) and two 2026-listed method patents US 12,544,379 and 12,544,380 (7 Aug 2034, PED 7 Feb 2035). | 20362036-10-14 | confirmed | FDA Orange Book data files (patent.txt, July 2026 edition) plus FDA Paragraph IV list last-qualifying-patent field |
3-year new-indication exclusivity code I-950 plus paediatric exclusivityThe Orange Book exclusivity file lists code I-950 against NDA 209092 (and I-951 against 209935) expiring 17 September 2027, plus a PED entry expiring 17 March 2028. The date is consistent with the September 2024 approval of Kisqali in adjuvant HR+/HER2- early breast cancer (NATALEE) plus three years. This is indication-specific only: an ANDA can carve the protected indication out of its label, so it does not block generic entry, only generic access to that indication. | 20282028-03-17 | confirmed | FDA Orange Book exclusivity data file (exclusivity.txt, July 2026 edition) |
Settled ANDA litigation - Novartis v. MSN Pharmaceuticals / Novadoz and Novartis v. Natco Pharma (D. Del.)Four ANDAs with Paragraph IV certifications were submitted on 15 March 2021. Novartis filed suit in the District of Delaware: 1:21-cv-00981 and 1:21-cv-01102 (MSN, July 2021), 1:23-cv-00550 (MSN, May 2023), 1:24-cv-01193 (MSN, Oct 2024) and 1:24-cv-01033 (Natco, Sept 2024), with an appeal Novartis AG v. Novadoz Pharmaceuticals (25-1550, 2025). Secondary litigation trackers report that the MSN matter ended in a confidential Settlement and License Agreement and that the Natco case was dismissed with prejudice on 1 May 2025. A settled ANDA case almost always carries a negotiated licensed entry date EARLIER than patent expiry, and that date is not public. Novartis's FY2025 Form 20-F does not disclose it. | Expiry not disclosed; unknown - confidential licensed entry date | litigation gated | CourtListener docket search for ribociclib (returns the Novartis v. MSN, Novartis v. Natco and Novartis v. Novadoz dockets) |
Earliest likely entry: 2031-09-13
The statutory clock is spent - NCE exclusivity expired in March 2022 and the remaining I-950 new-indication exclusivity (to Mar 2028 with paediatric) only forces a label carve-out, it does not block approval. The PATENT estate is what gates entry, and the binding layer is the composition-of-matter patent US 8,415,355 as extended, 13 Mar 2031, plus six months of paediatric exclusivity = 13 September 2031. That matches Novartis's own 20-F statement of US expiry 2031. Do NOT plan to the 14 Oct 2036 date that commercial trackers and even FDA's last-qualifying-patent field surface: those are drug-product/formulation patents that generics routinely design around, and the drug-substance patents run out five years earlier. The real-world date is probably EARLIER than 13 Sep 2031, because Novartis settled with MSN/Novadoz and Natco and settlements carry confidential licensed entry dates; four first-filer ANDAs share 180-day exclusivity. Separately, Kisqali was selected by CMS for the Medicare Drug Price Negotiation Program with a maximum fair price effective 2028 - a material US price event three years BEFORE any patent cliff, and for a US-heavy oncology brand that may matter more to the revenue curve than the LOE itself.
How to read this: The strongest-sourced record in this set. CONFIRMED (primary FDA sources): every patent number, expiry and paediatric-extended date comes from the FDA Orange Book patent and exclusivity data files (July 2026 edition, downloaded directly from FDA), not from a commercial tracker; the 15 March 2021 Paragraph IV submission date and the four-ANDA count come from FDA's own Paragraph IV Certifications list; the litigation dockets are real and verifiable; Novartis's FY2025 Form 20-F independently states US 2031 / EU 2032.
The 22-day PTE derivation for US 8,415,355 is arithmetic from the 14-year cap and matches the Orange Book date exactly. ESTIMATE: anything about the settlements. The licensed entry dates for MSN and Natco are confidential and the characterisation of the settlements relies on a secondary litigation tracker, not on the dockets themselves - if a generic appears before 2031 that will be why, and it is the single largest uncertainty in this record. Note also that the widely republished 14 October 2036 earliest-generic-entry figure is technically the last-expiring formulation patent, not a defensible LOE planning date.
Franchise view over one horizon (FY2025 → 2030): the adjuvant early breast cancer (natalee) base at risk, against the new indications modelled to replace it. Net $4.78B FY2025 → the $7.0B 2030 anchor.
Key model assumptionsAn Ormeval model, not company guidance. Both endpoints are the record's own - $4,783M reported for FY2025 (▲58% YoY) and a 2030 anchor of $7,000M - and the whole horizon sits BEFORE the cliff: composition protection runs to Jun 2028 but the latest Orange Book patents (US 9,193,732 and 9,868,739) run to Nov 2031, the record applies no erosion before 2031, and no generic is approved.
So this is not an exclusivity bridge at all. It is a bridge about how much of one label converts. Everything on the erosion side is competitive and evidential rather than legal: whether adjuvant guideline and formulary positions settle on monarchE's overall-survival result before NATALEE can produce one, and how much of Kisqali's broader eligible population survives its own tolerability. Novartis publishes no adjuvant-versus-metastatic revenue split, so neither side is scoped to a figure.
Adjuvant share, decided against an overall-survival result Kisqali cannot answer until 2030
The adjuvant growth engine
Lilly reported monarchE seven-year adjuvant overall survival at ESMO 2025 (HR 0.842, p=0.027). Novartis presented five-year NATALEE at the same congress and stated overall survival remains immature; NATALEE's listed primary completion is 29 May 2030. Tolerability bounds conversion on the other side - 20% of adjuvant patients permanently discontinued for an adverse reaction and 73% required a dose interruption. Full threat detail →
Modelled replacement · through 2030
the broadest adjuvant label in the classAdjuvant Stage II–III high risk, including node-negative
NATALEE · US 17 Sep 2024, EU 27 Nov 2024 · reaches patients Verzenio's node-positive-only adjuvant indication does not
Five-year durability
ESMO 2025 · 28.4% reduction in risk of recurrence · five-year iDFS 85.5% vs 81.0% · benefit sustained two years past the end of the three-year treatment period
The metastatic survival record
MONALEESA-2, -3 and -7 · the consistent OS dataset in the class, and the argument that moved prescribers off Ibrance in the first place
Class volume coming loose in 2027
The record's own palbociclib entry carries a Jan 2027 negotiated price and a Sep 2027 patent expiry with an AB-rated generic already approved; where that branded volume goes is unallocated, not assumed
Replacement wave is an Ormeval model scenario, not company guidance.
Net bridge · scenarios (Ormeval model)
Adjuvant guidelines and formularies settle on the trial that has an overall-survival result, and by the time NATALEE reads out in 2030 those positions are set. Tolerability compounds it: a fifth of adjuvant patients stopping and three quarters needing an interruption means the broader eligible population does not convert into treated years at the rate the label implies. Generic palbociclib from 2027 resets what a payer expects to pay for a CDK4/6 inhibitor in the metastatic setting. The line falls short of the $7.0B anchor.
The record's own anchor. Population size carries it: the node-negative and Stage IIA patients only Kisqali is labelled for are a genuinely larger pool, the five-year NATALEE durability holds the recurrence argument, and the MONALEESA survival record defends the metastatic base. No erosion applies anywhere in this horizon - the earliest patents fall in Nov 2031 - so the whole question is conversion, not defence.
Adjuvant WIDER (NCT05827081, primary completion Sep 2029) delivers close-to-practice adjuvant evidence in the broad population, real-world persistence proves better than the trial discontinuation rate suggests, Kisqali takes a disproportionate share of the branded volume freed when Ibrance goes generic in 2027, and NATALEE's mature overall survival arrives in 2030 to close the one evidential gap - just as the model's 2031 peak lands, ahead of the Nov 2031 patent expiries.
What would change our mindThe decisive readout is outside the horizon by design: NATALEE mature overall survival (NCT03701334) has a listed primary completion of 29 May 2030, so the evidence that would settle the adjuvant argument arrives at the far end of this bridge rather than inside it. Until then, watch the label rather than the podium - the current US prescribing information (effective 1 Jul 2026) still presents NATALEE at 36 months only, hazard ratio 0.749 with iDFS 90.7% versus 87.6%, and the five-year figures Novartis published in October 2025 are not in it. A payer reads the label. The day those five-year data appear in §14.1 is the day the durability argument becomes usable in access negotiations, and that is the nearest event that could move the replacement side of this bridge.
1 Product revenue as recorded by the company in the Company column, for scale within Kisqali's tracked competitive set, not the total market. 2 In USD at a fixed reference rate; % reported in the reporting currency. 3 As of Q2 2026 reported figures.
Contested revenue · who competes in the top settings
A rival's total revenue isn't a head-to-head number, competition happens setting by setting. For Kisqali's biggest revenue settings: the modelled revenue at stake and the rivals that actually compete for it.
Per-setting share, comparator and access-lag detail sit on each indication page. Tracked rivals (↗) link to their own asset page.
Zoom out: see how Novartis's launch wave offsets the LOE cliff →
What it shows. The rival agents to this asset and their scale, so you can see the competitive field it sits in.
What to look for. Which rivals overlap in the asset's biggest indications, and which are ex-US or a different line of therapy.
Common misread. A rival's total revenue is not a head-to-head number, competition happens indication by indication; use the indication pages for setting-level share.
Swipe to explore →Scroll sideways for every column →
| MONALEESA-2also MONALEESA-7, MONALEESA-3 | HR+/HER2- adv/met BC, 1L (+ aromatase inhibitor) | Approved | 63.9 mo · MONALEESA-2 OS (vs 51.4) | 2017-03-13 | App. 2017 | n/r | n/r | $1.81B (2023) |
| NATALEE | HR+/HER2- EARLY BC, adjuvant, Stage II–III high-risk (+ AI) | Approved | HR 0.749 · NATALEE iDFS | 2024-09-17 | App. 2024 | n/r | n/r | $4.23B (2029) |
Region columns show confirmed approval dates only. Est. peak is a model estimate, not a reported figure.
Provenance
The commercial question this section answers is whether an adjuvant population treated with curative intent will absorb an ECG-and-LFT calendar for three years.
Ribociclib carries no boxed warning, no REMS and no contraindication, but it carries the heaviest monitoring schedule in the CDK4/6 class: a baseline ECG with a QTcF entry gate, a repeat ECG at Day 14, electrolytes across six cycles, and LFTs and CBCs every two weeks at the start. The events themselves are largely reversible - QT prolongation resolved on interruption with no Torsades reported, and only about 1% of patients discontinued for neutropenia - so the profile constrains logistics rather than eligibility.
Toxicity is concentration-dependent, which is why the adjuvant NATALEE setting runs at 400 mg and reads milder on almost every category than the 600 mg advanced-disease label.
Ormeval viewThe commercial question this section answers is whether an adjuvant population treated with curative intent will absorb an ECG-and-LFT calendar for three years. NATALEE's lower 400 mg dose is the answer Novartis built: on the label's own figures nearly every category reads better at 400 mg than at 600 mg, and that gap is what makes the early-breast-cancer expansion defensible against a rival with no cardiac monitoring requirement.
Single-trial, arm-by-arm rates live on the indication pages: NATALEE: ribociclib + NSAI in early breast cancer, arm-by-arm →
Boxed warning
None
label 1 Jul 2026
None - the current SPL carries no boxed warning
REMS
None
label 1 Jul 2026
None - the string 'REMS' does not appear anywhere in the current SPL
Contraindications
None
label 1 Jul 2026
None - section 4 of the label reads 'None'
Use restrictions
Not recorded
label 1 Jul 2026
Pregnancy
Fetal harm
label 1 Jul 2026
Can cause fetal harm; effective contraception during therapy and for at least 3 weeks after the last dose
Bands are the label's own category-level framing. Rates are quoted verbatim and kept separate for the 400 mg early-breast-cancer setting (NATALEE) and the 600 mg advanced setting (MONALEESA-2/-3/-7), because ribociclib toxicity is concentration-dependent and the label deliberately never pools the two doses into a single incidence; postmarketing categories carry no incidence because frequency cannot be reliably estimated from spontaneous reports.
No notes for this section.
| What | When | Label section |
|---|---|---|
| Before starting | ECG in all patients, with initiation only below QTcF 450 ms; liver function tests; complete blood count; serum electrolytes including potassium, calcium, phosphorus and magnesium, corrected before starting. | · |
| On treatment | Repeat ECG around Day 14 of cycle 1 and as clinically indicated; electrolytes at the start of the first 6 cycles; LFTs and CBC every 2 weeks for the first 2 cycles then at the start of each of the next 4 cycles. | · |
| Avoid | Patients at significant risk of Torsades de Pointes (congenital long QT, significant cardiac disease, electrolyte abnormalities), concomitant QT-prolonging drugs, strong CYP3A inhibitors, and tamoxifen. | · |
| Hold / reduce / discontinue | Dose interruption, reduction or discontinuation per the label's dedicated tables for QT (Table 4), hepatobiliary toxicity (Table 5) and neutropenia (Table 6); permanent discontinuation for severe or recurrent ILD/pneumonitis and for confirmed SJS, TEN or DiHS/DRESS, with rechallenge prohibited after a SCAR. | · |
The synthesis across all indications. Editorial, grounded in the cited trial, guideline and access facts above.
What it shows. The franchise-level synthesis across all of the asset's indications, where the clinical, commercial, access and competitive reads net out.
What to look for. Whether the threats are asset-wide (loss of exclusivity, a class-wide rival) or specific to one indication, the asset-wide ones move the whole investment case.
Common misread. It's a running list, not a fixed verdict; each threat has catalysts that will resolve it, tracked on the catalyst calendar.
This SWOT is synthesised from the cited pivotal-trial readouts and the company’s investor-relations filings referenced in the badges above. Each point nets the relevant clinical, commercial and competitive evidence into a single franchise-level read; the tags identify the anchoring trial or source behind the underlying data.
Other tracked Novartis franchises, sorted by reported revenue. Each links to its own asset page.
| Product | Therapy area | Trajectory | Revenue | YoY | QoQ | US LOE | Approved | Pipeline |
|---|---|---|---|---|---|---|---|---|
| Entresto | Cardiovascular & Metabolic | $7.75BFY25 | −$74.0M▼ 1% vs FY24 | $1.18B▼ 10% vs Q1 2026 | ~2025lapsed | 3 | 0 | |
| Cosentyx | Immunology & Respiratory | $6.67BFY25 | +$527M▲ 9% vs FY24 | $1.82B▲ 16% vs Q1 2026 | ~2029 | 5 | 1 | |
| Kesimpta | Other | $4.43BFY25 | +$1.20B▲ 37% vs FY24 | $1.42B▲ 22% vs Q1 2026 | ~2032 | 1 | 1 | |
| Tafinlar + Mekinist | Oncology | $2.21BFY25 | +$157M▲ 8% vs FY24 | $581M▲ 18% vs Q1 2026 | ~2027 | 6 | 0 | |
| Jakavi | Oncology | $2.11BFY25 | +$174M▲ 9% vs FY24 | $576M▲ 3% vs Q1 2026 | ~2028 | 4 | 0 |
Every reported figure on this page traces to one of the public sources below. Forward figures are model estimates and are labelled as such.Sourced · as of Q2 2026
Reported figures are public facts transcribed from company investor materials and SEC filings. The outlook curve, modelled peak and loss-of-exclusivity timing are flagged Ormeval model projections, not analyst consensus. For decision-support only: not investment, financial, or medical advice. Follow this asset to build an editable, deterministic forecast around these anchors.